BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 33116249)

  • 1. Identification of SARS-CoV-2 entry inhibitors among already approved drugs.
    Yang L; Pei RJ; Li H; Ma XN; Zhou Y; Zhu FH; He PL; Tang W; Zhang YC; Xiong J; Xiao SQ; Tong XK; Zhang B; Zuo JP
    Acta Pharmacol Sin; 2021 Aug; 42(8):1347-1353. PubMed ID: 33116249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repositioning of histamine H
    Ge S; Wang X; Hou Y; Lv Y; Wang C; He H
    Eur J Pharmacol; 2021 Apr; 896():173897. PubMed ID: 33497607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A high throughput screening assay for inhibitors of SARS-CoV-2 pseudotyped particle entry.
    Xu M; Pradhan M; Gorshkov K; Petersen JD; Shen M; Guo H; Zhu W; Klumpp-Thomas C; Michael S; Itkin M; Itkin Z; Straus MR; Zimmerberg J; Zheng W; Whittaker GR; Chen CZ
    SLAS Discov; 2022 Mar; 27(2):86-94. PubMed ID: 35086793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identifying FDA-approved drugs with multimodal properties against COVID-19 using a data-driven approach and a lung organoid model of SARS-CoV-2 entry.
    Duarte RRR; Copertino DC; Iñiguez LP; Marston JL; Bram Y; Han Y; Schwartz RE; Chen S; Nixon DF; Powell TR
    Mol Med; 2021 Sep; 27(1):105. PubMed ID: 34503440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kite-Shaped Molecules Block SARS-CoV-2 Cell Entry at a Post-Attachment Step.
    Chan SW; Shafi T; Ford RC
    Viruses; 2021 Nov; 13(11):. PubMed ID: 34835112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Azelastine inhibits viropexis of SARS-CoV-2 spike pseudovirus by binding to SARS-CoV-2 entry receptor ACE2.
    Ge S; Lu J; Hou Y; Lv Y; Wang C; He H
    Virology; 2021 Aug; 560():110-115. PubMed ID: 34052578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of potent small molecule inhibitors of SARS-CoV-2 entry.
    Mediouni S; Mou H; Otsuka Y; Jablonski JA; Adcock RS; Batra L; Chung DH; Rood C; de Vera IMS; Rahaim R; Ullah S; Yu X; Getmanenko YA; Kennedy NM; Wang C; Nguyen TT; Hull M; Chen E; Bannister TD; Baillargeon P; Scampavia L; Farzan M; Valente ST; Spicer TP
    SLAS Discov; 2022 Jan; 27(1):8-19. PubMed ID: 35058179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mapping the SARS-CoV-2-Host Protein-Protein Interactome by Affinity Purification Mass Spectrometry and Proximity-Dependent Biotin Labeling: A Rational and Straightforward Route to Discover Host-Directed Anti-SARS-CoV-2 Therapeutics.
    Terracciano R; Preianò M; Fregola A; Pelaia C; Montalcini T; Savino R
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33430309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening of Natural Products Inhibitors of SARS-CoV-2 Entry.
    González-Maldonado P; Alvarenga N; Burgos-Edwards A; Flores-Giubi ME; Barúa JE; Romero-Rodríguez MC; Soto-Rifo R; Valiente-Echeverría F; Langjahr P; Cantero-González G; Sotelo PH
    Molecules; 2022 Mar; 27(5):. PubMed ID: 35268843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of SARS-CoV-2 Receptor Binding Inhibitors by In Vitro Screening of Drug Libraries.
    David AB; Diamant E; Dor E; Barnea A; Natan N; Levin L; Chapman S; Mimran LC; Epstein E; Zichel R; Torgeman A
    Molecules; 2021 May; 26(11):. PubMed ID: 34072087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenothiazines inhibit SARS-CoV-2 cell entry via a blockade of spike protein binding to neuropilin-1.
    Hashizume M; Takashima A; Ono C; Okamoto T; Iwasaki M
    Antiviral Res; 2023 Jan; 209():105481. PubMed ID: 36481388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19.
    Mirabelli C; Wotring JW; Zhang CJ; McCarty SM; Fursmidt R; Pretto CD; Qiao Y; Zhang Y; Frum T; Kadambi NS; Amin AT; O'Meara TR; Spence JR; Huang J; Alysandratos KD; Kotton DN; Handelman SK; Wobus CE; Weatherwax KJ; Mashour GA; O'Meara MJ; Chinnaiyan AM; Sexton JZ
    Proc Natl Acad Sci U S A; 2021 Sep; 118(36):. PubMed ID: 34413211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of ACE2-Spike Interaction by an ACE2 Binder Suppresses SARS-CoV-2 Entry.
    Shin YH; Jeong K; Lee J; Lee HJ; Yim J; Kim J; Kim S; Park SB
    Angew Chem Int Ed Engl; 2022 Mar; 61(11):e202115695. PubMed ID: 35043545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic antibodies and fusion inhibitors targeting the spike protein of SARS-CoV-2.
    Jiang S; Zhang X; Du L
    Expert Opin Ther Targets; 2021 Jun; 25(6):415-421. PubMed ID: 32941780
    [No Abstract]   [Full Text] [Related]  

  • 15. Screening of Botanical Drugs against SARS-CoV-2 Entry Reveals Novel Therapeutic Agents to Treat COVID-19.
    Cao J; Liu Y; Zhou M; Dong S; Hou Y; Jia X; Lan X; Zhang Y; Guo J; Xiao G; Wang W
    Viruses; 2022 Feb; 14(2):. PubMed ID: 35215943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effective Inhibition of SARS-CoV-2 Entry by Heparin and Enoxaparin Derivatives.
    Tandon R; Sharp JS; Zhang F; Pomin VH; Ashpole NM; Mitra D; McCandless MG; Jin W; Liu H; Sharma P; Linhardt RJ
    J Virol; 2021 Jan; 95(3):. PubMed ID: 33173010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.
    Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M
    Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification, optimization, and biological evaluation of 3-O-β-chacotriosyl ursolic acid derivatives as novel SARS-CoV-2 entry inhibitors by targeting the prefusion state of spike protein.
    Li H; Cheng C; Shi S; Wu Y; Gao Y; Liu Z; Liu M; Li Z; Huo L; Pan X; Liu S; Song G
    Eur J Med Chem; 2022 Aug; 238():114426. PubMed ID: 35551037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Updated Review on Betacoronavirus Viral Entry Inhibitors: Learning from Past Discoveries to Advance COVID-19 Drug Discovery.
    Sabbah DA; Hajjo R; Bardaweel SK; Zhong HA
    Curr Top Med Chem; 2021; 21(7):571-596. PubMed ID: 33463470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Replication-Competent Vesicular Stomatitis Virus for Studies of SARS-CoV-2 Spike-Mediated Cell Entry and Its Inhibition.
    Dieterle ME; Haslwanter D; Bortz RH; Wirchnianski AS; Lasso G; Vergnolle O; Abbasi SA; Fels JM; Laudermilch E; Florez C; Mengotto A; Kimmel D; Malonis RJ; Georgiev G; Quiroz J; Barnhill J; Pirofski LA; Daily JP; Dye JM; Lai JR; Herbert AS; Chandran K; Jangra RK
    Cell Host Microbe; 2020 Sep; 28(3):486-496.e6. PubMed ID: 32738193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.